2Bone RC.Balk RA,Cerra FB,et al.Definitions of sepsis and organ failure and guidelines for the use of innovative therapies.The ACCP/SCCM Consensus Conference Committee.Chest,1992.101:1644-1655.
1Tian J. Hydroxyethyl starch and capillary leak syndrome [J]. Anesth Analg,2004,98 (3) :768 - 774.
2陈德昌.有关严重感染患者早期输液复苏治疗的探讨[N].中国医学论坛报,2004年6月3日第8版.
3Marx G, Vangerow B, Burczyk C, et al. Evaluation of noninvasive determinants for capillary leakage syndrome in septic shock patients [J].Intensive Care Med,2000,26(9): 1252 - 1258.
4Margarson MP, Soni NC. Changes in serum albumin concentration and volume expanding effects following a bolus of albumin 20% in septic patients[J]. Br J Anaesth,2004,92(6) :821 - 826.
5Haisch G. The influence of intravascular volume therapy with a new hydroxyethyl starch(6% HES 130/0.4) compared to 4% modified fluid Gelatin[J]. Anesth Analg,2001,92,565 - 571.
6Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomized controlled trials (RCT) [J]. British Medical Journal, 1998,317:235 - 240.
10Alto H, Takala A, Kautiainen H, et at. Laboratory markers of systemic inflammation as predictors of bloodstream infection in acutely ill patients admitted to hospital in medical emergency[J]. Eur Clin Microbiol Infect Dis,2004,23(9) :699-704.
